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Background: Benzodiazepines and related drugs affect physical functioning negatively and increase fall and
fracture risk. As impaired muscle strength and balance are risk factors for falls, we examined the effects of hypnotic
withdrawal on handgrip strength and balance in older adult outpatients during and after long-term use of
temazepam, zopiclone and zolpidem (here collectively referred to as “benzodiazepines”).
Methods: Eighty-nine chronic users (59 women, 30 men) of temazepam, zopiclone or zolpidem aged ≥55 years
participated in a benzodiazepine withdrawal study. Individual physician-directed withdrawal was performed
gradually over a one-month period and participants were followed up to six months. Handgrip strength was
assessed using a handheld dynamometer, and balance using the Short Berg’s Balance Scale during the period of
benzodiazepine use (baseline), and at 1, 2, 3 weeks, and 1, 2 and 6 months after initiating withdrawal. Withdrawal
outcome and persistence were determined by plasma benzodiazepine-determinations at baseline and at four
weeks (“short-term withdrawers”, n = 69; “short-term non-withdrawers”, n = 20), and by interviews at six months
(“long-term withdrawers”, n = 34; “long-term non-withdrawers”, n = 55). Also most of the non-withdrawers markedly
reduced their benzodiazepine use.
Results: Within three weeks after initiating withdrawal, handgrip strength improved significantly (P ≤ 0.005)
compared to baseline values. Among women, long-term withdrawers improved their handgrip strength both when
compared to their baseline values (P = 0.001) or to non-withdrawers (P =0.004). In men, improvement of handgrip
strength from baseline was not significantly better in withdrawers than in non-withdrawers. However, men did
improve their handgrip strength values compared to baseline (P = 0.002). Compared to balance test results at
baseline, withdrawers improved starting from the first week after withdrawal initiation. There was, however, only a
borderline difference (P = 0.054) in balance improvement between the long-term withdrawers and long-term
non-withdrawers. Of note, the non-withdrawers tended to improve their handgrip strength and balance compared
to baseline values, in parallel with their reduced benzodiazepine use.
Conclusions: Withdrawal from long-term use of benzodiazepines can rapidly improve muscle strength and balance.
Our results encourage discontinuing benzodiazepine hypnotics, particularly in older women who are at a high risk
of falling and sustaining fractures.
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Benzodiazepines and benzodiazepine related drugs (here
collectively referred to as “benzodiazepines”) are widely
used to treat insomnia and other conditions in older
adults [1-3]. Their adverse effects include a decline in
physical functioning [4] and an increased risk for falls
and fractures [5-7]. Benzodiazepines are a major cause
of hospitalization, permanent loss of physical function
and even death [8]. Fall and fracture prevention studies
show that withdrawal of psychotropic drugs decreases
older adults’ risk of falling [9,10].
Impaired balance and muscle strength are associated
with falls, especially in older adults [11]. Benzodiaze-
pines can affect balance and physical functioning nega-
tively [12,13]. However, most studies in this field have
examined benzodiazepine-effects following a single dose,
and longitudinal studies have yet to be performed [14].
One mechanism for the possible reduction of risk of falls
and fractures after benzodiazepine withdrawal could be
enhanced balance and muscle strength. Although the use
of psychoactive medications has been connected to low-
ered muscle strength [15], clinical studies specifically
concerning benzodiazepines and muscle strength are
rare [16].
Only a few studies exist on the effect of withdrawal from
long-term use of benzodiazepines on muscle strength and
balance in older adults [17,18]. These studies reported
improved daily functions and balance in nursing home
residents after benzodiazepine withdrawal. However, the
study by Habraken et al. relied exclusively on observa-
tional data to assess the level of daily functioning during
and after lorazepam use [17]. The study by Tsunoda et al.
had a relatively small sample size and the population was
rather selected as most of their subjects had schizophrenia
or dementia [18]. Furthermore, no subjects in these
two studies [17,18] was using temazepam, zopiclone or
zolpidem.
The aim of the current study was to assess whether
withdrawal from long-term use of temazepam, zopiclone
or zolpidem enhances handgrip strength and balance in
older outpatients – a question that has not previously been
the subject of rigorous research.
Methods
Study design and participants
This study is a part of the Satauni Study, a prospective
benzodiazepine withdrawal study, details of which are re-
ported elsewhere [19,20]. The Study protocol was approved
by the Ethics Committee of Satakunta Hospital District
and by the National Agency for Medicines of Finland (EU
Clinical Trials Register: EudraCT2008000679530). A writ-
ten informed consent was received from each participant
before they entered the trial in which the participant’sbenzodiazepine dose was planned to be tapered off over a
one month period.
Participants were primary health care outpatients liv-
ing in the Province of Satakunta in western Finland [19].
Persons 55 years of age or over who had been using tem-
azepam, zopiclone or zolpidem as hypnotics on a regular
long-term basis (night-time use >1 month prior to enroll-
ment) to treat primary insomnia were included in the study
(Figure 1). A nurse performed the preliminary telephone or
e-mail screenings, and a physician met the potential
participants for screening, recruitment and to obtain
informed consent [19]. The main exclusion criteria were
use of antipsychotic or antiepileptic medication or benzo-
diazepines other than those identified above; a current or
past history of alcohol or drug abuse; severe psychiatric,
neurological or autoimmune disease; and smoking more
than 10 cigarettes a day. Of the 211 subjects assessed for
eligibility, 83 did not meet the inclusion criteria, 36
declined to participate and 3 withdrew from the study.
Eighty nine outpatients (59 women and 30 men; mean
age 67; range 55–91 years) met the criteria. Individual
physician-directed withdrawal was performed gradually
over a one-month period and participants were followed
up to six months (Figure 1). Participants’ handgrip strength
and balance test data are reported in the present study. In
the original Satauni Study melatonin (2 mg) was compared
double-blindly to placebo. It reported that patients neither
benefited from melatonin use in benzodiazepine with-
drawal nor did the melatonin cause adverse effects [19].
Based on that result, data from the both groups were
pooled and analyzed together in this study.
Measurement and classifications
At baseline (that is, before initiating withdrawal) data
concerning health behavior, diseases, sleep behavior and
medication use were collected and a thorough clinical
examination was performed [19]. Venous blood samples
were taken at baseline and one month after the start of
withdrawal to determine the residual plasma concentra-
tion of benzodiazepines (procedure details are described
elsewhere [19]). Participants with no plasma concentra-
tion of benzodiazepine at one month after the start of
the withdrawal were classified as short-term withdrawers
(n = 69), and those with a measurable concentration as
short-term non-withdrawers (n = 20) (Figure 1). The div-
ision of participants into long-term withdrawers (n = 34)
and long-term non-withdrawers (n = 55; including 44
irregular users and 11 daily users) was determined by in-
terviewing the participants and checking their medical
records and prescriptions in detail over the six months
period after the start of withdrawal [19]. The demographic
data at baseline for the short-term withdrawers and
non-withdrawers as well as long-term withdrawers and
non-withdrawers are given in Table 1. Most of the non-
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Recruitment took place between 16 February 2009 and 14 January 2010. Personnel at 
local health centres recruited patients, and two advertisements were placed in a local 
newspaper.
Assessed for eligibility (N=211)
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Baseline measurements and counselling (N=92)
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– sleep hygiene counselling and individual withdrawal plan 
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One-month withdrawal period
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Short-term non-withdrawers (N=20)
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– measurements
Visit (N=20)
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(N=44)
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(N=11)
– not meeting inclusion criteria 
(N=83)
– declined to participate (N=36)
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Visit (N=20)
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N=4 N=36 N=8 N=3 N=8
Figure 1 Benzodiazepine withdrawal study flow chart. Legend: There were two dropouts at week 3 and one at week 6.
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benzodiazepine use, and many of those were without
benzodiazepines for several weeks or months, but they
were classified as non-withdrawers if they were not abstin-
ent up to the 6 month mark. At baseline, the short-term
withdrawers and non-withdrawers did not differ by age,
gender, marital status, education, body measures, self-
reported quality of life, number of medications, duration
of benzodiazepine use or alcohol consumption, as de-
scribed elsewhere [19]. However, there were more smokers
among the short-term non-withdrawers. The short-term
non-withdrawers also had more depressive symptoms than
did the short-term withdrawers.
Handgrip strength and balance measurements
Handgrip strength and balance were measured during
this prospective study at baseline (immediately beforethe withdrawal), and at 1, 2, 3, and 4 weeks after beginning
the withdrawal, and at the 2 and 6 month follow-ups.
Handgrip strength and balance measurements were per-
formed by a trained nurse blinded to withdrawal success
and persistence of benzodiazepine abstinence.
Handgrip strength (both hands three times consecu-
tively) was measured with a Saehan (Jamar®) dynamometer
in kilograms (kg) [21]. The average value of the stronger
hand was recorded. Balance was assessed with Short Berg’s
Balance Scale (BBS-9) [22], a 9-item version of the original
BBS [23]. The BBS-9’s range is from 0 to 36 [22]. Data on
the BBS-9 was divided into two groups, i.e. participants
scoring less than 33 points and those scoring 33 points or
more. There were two reasons why BBS-9 scores were not
used as a continuous variable. First, scores below 33 are
associated with increased fall risk [24], and second, distri-
bution of BBS-9 scores was extremely negatively skewed.
Table 1 Demographic data at baseline
Short-term
withdrawers
Short-term
non-withdrawers
Long-term
withdrawers
Long-term
non-withdrawers
N = 69 N = 20 N = 34 N = 55
(45 women, 24 men) (14 women, 6 men) (19 women, 15 men) (40 women, 15 men)
Age, years (mean ± SD) 67 ± 7 67 ± 6 65 ± 7 68 ± 7
Number of medications (median [LQ, UQ]) 4.0 [3.0, 5.0] 4.0 [3.0, 5.5] 4.0 [3.0, 6.0] 4.0 [3.0, 5.0]
N N N N
Duration of benzodiazepine use
Less than 5 years 12 2 6 8
5 to 10 years 34 8 17 25
10 years or longer 23 10 11 22
Benzodiazepine use (daily dose range)
Temazepam (10–30 mg) 9 4 3 10
Zopiclone (3.75-30 mg) 39 11 19 31
Zolpidem (5–20 mg) 21 5 12 14
Depression
Not depressed (GDS-15 sum score <6) 63 16 32 47
Depressed (GDS-15 sum score ≥6) 5 4 2 7
Smoking
Non-smoker 67 16 32 51
Smoker 2 4 2 4
Use of alcohol
Non-user 16 1 5 12
Once a month or more seldom 25 6 13 18
2-4 times a month 17 9 9 17
2 times a week or more often 10 3 7 6
Self-reported health
Good 17 1 9 9
Fair 44 14 18 40
Poor 8 5 7 6
N = number of participants.
GDS-15 = Geriatric Depression Scale (15 point version).
SD = Standard deviation.
LQ = Lower quartile.
UQ = Upper quartile.
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Participants who had used temazepam, zopiclone or
zolpidem were analyzed together because the small
numbers of users of the individual drugs did not allow
adequate statistical power (Table 1). At baseline, differ-
ences between the withdrawers and non-withdrawers were
tested with the Mann–Whitney U-test, two-sample t-test
or χ2 -test.
As the mean handgrip strength (±SD) of men at base-
line, 42.4 kg (6.2 kg), was significantly (P < 0.001) greater
than that of women, 22.8 kg (5.2 kg), their data was ana-
lyzed separately. Handgrip strength between withdrawers
and non-withdrawers was compared at baseline and during
subsequent time points with repeated measures analysis ofvariance using a heterogeneous compound symmetry
covariance structure. Group (short-term withdrawers/
non-withdrawers; long-term withdrawers/non-withdrawers)
was used as a fixed factor and time was used as a repeated
factor. Interaction effects of group × time were also tested.
Dunnett’s multiple comparison method was used in com-
paring different follow-up time points to baseline.
For the balance analyses, we pooled data from men and
women, since there was no statistically significant dif-
ference in the BBS-9 data between the genders at baseline
(P = 0.924). BBS-9 scores (≥33 vs. <33) were compared be-
tween withdrawers and non-withdrawers at baseline and
during subsequent time points. Binary logistic regression
analysis with generalized estimating equations (GEE) with
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Group was treated as a fixed factor and time was treated
as a repeated factor in the logistic model. Interaction
effects of group × time were also tested.
P-values less than 0.05 were considered as statistically
significant. SAS version 9.2 and SAS Enterprise Guide
4.1 (SAS Institute Inc., Cary, NC, USA) were used in the
statistical analyses.
Results
Demographic data at baseline and withdrawal results
Baseline data collected before initiating withdrawal is given
in Table 1. In this table, the results are presented separately
for short-term withdrawers and non-withdrawers as well
as for long-term withdrawers and non-withdrawers. There
were more smokers among short-term non-withdrawers
than short-term withdrawers (P = 0.022). No other statisti-
cally significant differences were found for the variables
presented in Table 1.
It is noteworthy that many of the non-withdrawers
(both men and women) had also reduced their benzodi-
azepine use. At baseline, all participants were daily users
of benzodiazepines. Six months after withdrawal initiation,
19 women and 15 men had completely stopped using ben-
zodiazepines. Furthermore, 28 women and nine men were
using benzodiazepines once a week or less frequently, and
four women and three men were using a hypnotic 2–6
times a week, respectively. Eight women and three men
were daily users of benzodiazepines at six months after
beginning of the withdrawal.Table 2 Handgrip strength (kg) in women (n = 59) by success o
withdrawal
ONE MONTH (short-term withdrawal) Me
Baseline 1 week 2 weeks
mean, SD mean, SD mean, SD
short-term withdrawers (n = 45) 23.5, 24.2, 24.4,
5.4 5.8 5.5
short-term non-withdrawers (n = 14) 20.4, 21.0, 19.9,
4.1 4.5 4.1
SIX MONTHS (long-term withdrawal) Me
Baseline 1 week 2 weeks
mean, SD mean, SD mean, SD
long-term withdrawers (n = 19) 23.3, 24.1, 24.7,
5.4 6.7 5.6
long-term non-withdrawers (n = 40) 22.5, 23.1, 22.7,
5.2 5.2 5.4
P1 = Statistical significance for group × time interaction effect; repeated measures a
P2 = Statistical significance for group effect; repeated measures analysis of variance
P3 = Statistical significance for time effect; repeated measures analysis of variance u
handgrip strength was better* at 3 weeks (P = 0.002), at 1 month (P = 0.004), at 2 m
P4 = Statistical significance for time effect within groups; repeated measures analys
1 month (P = 0.006), at 2 months (P < 0.001) and at 6 months (P = 0.003) among w
SD = Standard deviation.Handgrip strength in women
Among women, handgrip strength improved significantly
starting from the third withdrawal week when compared
to baseline values both in the short-term withdrawers
(n = 45) and short-term non-withdrawers (n = 14)
(P ≤ 0.005; Table 2). Women who were benzodiazepine-
free at 6 months (n = 19; “long-term withdrawers”) im-
proved their handgrip strength more than those who were
not benzodiazepine-free at 6 months (n = 40; “non-with-
drawers”) (group × time interaction effect P = 0.040;
Figure 2). In the long-term withdrawers handgrip strength
was better at 3 weeks, 1 month, 2 months and 6 months
compared to baseline values (P ≤ 0.006; Table 2).
Handgrip strength in men
Among men, handgrip strength improved significantly
compared to baseline values both in the short-term with-
drawers (n = 24) and non-withdrawers (n = 6) (P = 0.002).
A significant improvement in strength was seen also in
those men who were benzodiazepine-free at 6 months
(n = 15; long-term withdrawers) as well as in those who
were not completely benzodiazepine abstinent at 6 months
(n = 15; long-term non-withdrawers) (P = 0.002; Table 3).
Balance test: short Berg’s balance scale (BBS-9)
Balance (BBS-9 score) improved in all groups compared
to baseline data (Figure 3). The improvement was signifi-
cant in short-term and long-term withdrawers from the
first week after initiating withdrawal (P ≤ 0.003; Table 4).
However, the changes in BBS-9 scores did not differf short-term (“ONE MONTH”) and long-term (“SIX MONTHS”)
asurement point
3 weeks 1 month 2 months 6 months
mean, SD mean, SD mean, SD mean, SD P1 P2 P3
24.8*, 24.7*, 24.9*, 24.8*, 0.350 0.032 0.003
5.6 5.7 5.5 5.8
20.3, 21.0, 21.2, 20.8,
5.7 5.5 5.8 6.2
asurement point
3 weeks 1 month 2 months 6 months
mean, SD mean, SD mean, SD mean, SD P1 P4
25.6§, 25.2§, 25.6§, 25.3§, 0.040 0.001
5.9 5.7 5.6 5.5
22.9, 23.1, 23.1, 23.2, 0.427
5.8 5.8 5.7 6.3
nalysis of variance.
; adjusted for time.
sing Dunnett’s method in pairwise comparisons. After adjustment for group,
onths (P = 0.005), and at 6 months (P = 0.004) compared to baseline.
is of variance. Handgrip strength was better§ at 3 weeks (P = 0.005), at
ithdrawers compared to baseline.
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Figure 2 Associations between medication withdrawal result
and handgrip strength in women. Legend: Mean (± standard
error) of handgrip strength (kg) in women (n = 59) by success of
long-term (“SIX MONTHS”) withdrawal at different time points
(0 = before withdrawal, at 1, 2, 3 and 4 weeks after beginning of
withdrawal, and at 2 and 6 months follow-up period). Women who
were benzodiazepine-free at 6 months (n = 19; “long-term withdrawers”)
improved their handgrip strength more than those who were not
benzodiazepine-free at 6 months (n = 40; “non-withdrawers”)
(group × time interaction effect P = 0.040). The long-term withdrawers
had better handgrip strength (P≤ 0.006) from week 3 on than at
baseline (week 0).
Table 3 Handgrip strength (kg) in men (n = 30) by success of s
withdrawal
ONE MONTH (short-term
withdrawal)
Me
Baseline 1 week 2 weeks
mean, SD mean, SD mean, SD
short-term withdrawers (n = 24) 42.9, 44.9*, 44.6*,
6.5 5.7 6.6
short-term non-withdrawers (n = 6) 40.3, 44.0*, 42.8*,
5.8 7.0 6.2
SIX MONTHS (long-term withdrawal) Me
Baseline 1 week 2 weeks
mean, SD mean, SD mean, SD
long-term withdrawers (n = 15) 41.5, 43.5§, 43.7§,
5.6 5.5 5.4
long-term non-withdrawers (n = 15) 43.3, 46.0§, 45.0§,
7.1 6.1 7.5
P1 = Statistical significance for group × time interaction effect; repeated measures a
P2 = Statistical significance for group effect; repeated measures analysis of variance
P3 = Statistical significance for time effect; repeated measures analysis of variance u
one month’s time point handgrip strength was better* at 1 week (P = 0.002), at 2 w
(P = 0.001), and at 6 months (P = 0.006) compared to baseline. After adjustment for
(P = 0.002), at 2 weeks (P = 0.002), at 3 weeks (P = 0.001), at 1 month (P = 0.013), a
SD = Standard deviation.
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(P = 0.474; Table 4). Changes in BBS-9 scores reached
borderline significance between the long-term withdrawers
and non-withdrawers (group × time interaction effect,
P = 0.054), but there was no difference in BBS-9 scores
between groups (group effect P = 0.165).
Discussion
Our results demonstrate that withdrawal from temaze-
pam, zopiclone and zolpidem can significantly improve
handgrip strength and balance in older adults who have
been long-term users of these hypnotics. The improve-
ment starts rapidly, during the first weeks after initiating
gradual benzodiazepine withdrawal. Some improvement
was seen also in those participants who decreased their
benzodiazepine use but did not completely discontinue
it. These subjects are described here as short-term or
long-term non-withdrawers, and their hypnotic use and
other characteristics are described in more detail else-
where [19,20].
Handgrip strength is a recommended measurement to
assess overall muscle strength [25]. We used the Seahan
(Jamar®) handheld dynamometer to measure the patients’
maximal handgrip strength in standard testing conditions.
The baseline handgrip strength results from our study
are comparable with reference values from a sample of
Finnish adults over 50 years of age [26]. Since there was a
statistically significant gender difference concerning hand-
grip strength results, we analyzed men and women separ-
ately. This was necessary in order to study the true effecthort-term (“ONE MONTH”) and long-term (“SIX MONTHS”)
asurement point
3 weeks 1 month 2 months 6 months
mean, SD mean, SD mean, SD mean, SD P1 P2 P3
44.6*, 44.5*, 44.5*, 44.2*, 0.296 0.619 0.002
5.5 6.5 5.2 6.0
41.5*, 41.9*, 43.6*, 43.9*,
6.0 6.6 7.7 8.4
asurement point
3 weeks 1 month 2 months 6 months
mean, SD mean, SD mean, SD mean, SD P1 P2 P3
43.7§, 43.7§, 44.4§, 43.9§, 0.357 0.897 0.002
5.2 6.3 4.5 5.5
44.6§, 44.2§, 44.2§, 44.3§,
6.1 6.9 6.8 7.4
nalysis of variance.
; adjusted for time.
sing Dunnett’s method in pairwise comparisons. After adjustment for group at
eeks (P = 0.001), at 3 weeks (P = 0.001), at 1 month (P = 0.013), at 2 months
group at six months’ time point handgrip strength was better§ at 1 week
t 2 months (P = 0.001), and at 6 months (P = 0.006) compared to baseline.
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Figure 3 Effect of medication withdrawal on balance. Legend:
Effect of short-term and long-term withdrawal from chronic daily
use of temazepam, zopiclone and zolpidem on balance in older
adults assessed using the Short Berg’s Balance Scale (BBS-9). The
percentage of participants at increased fall risk (<33 points) at baseline
and at different time points after the beginning of withdrawal are
shown. Of note, most of the non-withdrawers also reduced their
hypnotic use and were temporarily abstinent.
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decreased sample size. This must be considered as a
limitation.
Both muscle weakness and poor balance are risk fac-
tors for falls [11,27], and benzodiazepines are known to
impair muscle strength and balance [16,28]. Even though
the fundamental aim of the present study was to provide
tools for fall and fracture prevention in a clinical context,
this study was not designed to register participants’ falls.Table 4 Balance* by success of short-term (“ONE MONTH”) an
ONE MONTH (short-term withdrawal) M
Baseline 1 week 2 weeks
n (%) n (%) n (%)
short-term withdrawers under 33 points† 27 (40) 19 (28) 17 (25)
short-term non-withdrawers under 33 points† 7 (35) 5 (26) 4 (22)
SIX MONTHS (long-term withdrawal) M
Baseline 1 week 2 weeks
n (%) n (%) n (%)
long-term withdrawers under 33 points† 10 (30) 8 (25) 4 (12)
long-term non-withdrawers under 33 points† 24 (44) 16 (30) 17 (32)
*Using Short Berg’s Balance Scale (BBS-9).
Note: Number of withdrawers and non-withdrawers under 33 points (and their perc
P1 = Statistical significance for group × time interaction effect; logistic regression an
P2 = Statistical significance for group effect; logistic regression analysis using GEE e
P3 = Statistical significance for time effect; logistic regression analysis using GEE est
balance was better at 1 week (P = 0.003), 2 weeks (P = 0.003), at 3 weeks (P < 0.001
compared to baseline. After adjustment for gender and group at six months’ time p
3 weeks (P < 0.001), at 1 month (P < 0.001), at 2 months (P < 0.001), and at 6 month
†Cut off -point (<33) suggests increased fall risk [24].
Men and women combined (n = 89).However, when the 89 participants were repeatedly inter-
viewed during the 6 months, only one fracture was re-
ported. A man had fallen from ladders when cleaning
eaves and sustained a high-energy fracture of acetabulum.
Previous studies have not examined chronic users of
these benzodiazepine hypnotics for a possible influence
of withdrawal on muscle strength. All of our patients
were relatively healthy outpatients, and, until rapid with-
drawal in this study, most of them had used benzodiaze-
pines as hypnotics daily for more than five years. Our
recent study revealed that both attentional and psycho-
motor cognitive functioning of these same patients was
impaired during benzodiazepine use at baseline when
compared to a benzodiazepine-naïve control group [20].
Furthermore, cognitive impairment was still present in
these subjects after 6 months of benzodiazepine abstin-
ence suggesting a possibility of prolonged neuronal ad-
verse effects [20]. In the present study an improvement
in muscle strength and balance in the same patients
could be observed starting from one to three weeks from
the beginning of the withdrawal process. This finding is
encouraging for clinicians working with older adults,
many of whom are chronic users of benzodiazepine
hypnotics.
The short version of Berg’s Balance Scale (BBS-9) was
used to estimate participants’ balance. BBS-9 strongly
correlates with the original BBS, and it takes a shorter
time to complete [22]. Although the original BBS has
been criticized for having a ceiling effect among higher-
functioning older adults, BBS-9 might avoid this effect
[22,24]. It can be speculated that if the participants were
more frail, the differences between withdrawers and
non-withdrawers might have been detected more clearly.d long-term (“SIX MONTHS”) withdrawal
easurement point
3 weeks 1 month 2 months 6 months
n (%) n (%) n (%) n (%) P1 P2 P3
14 (21) 13 (19) 9 (13) 9 (13) 0.474 0.997 <0.001
2 (11) 5 (26) 4 (24) 1 (6)
easurement point
3 weeks 1 month 2 months 6 months
n (%) n (%) n (%) n (%) P1 P2 P3
4 (12) 3 (9) 3 (9) 2 (6) 0.054 0.165 <0.001
12 (23) 15 (27) 10 (20) 8 (15)
entage from all participants) at different time points are given.
alysis using GEE estimation; adjusted for gender.
stimation; adjusted for gender and time.
imation. After adjustment for gender and group at one month’s time point
), at 1 month (P < 0.001), at 2 months (P < 0.001), and at 6 months (P < 0.001)
oint balance was better at 1 week (P = 0.003), at 2 weeks (P = 0.003), at
s (P < 0.001) compared to baseline.
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benzodiazepine withdrawal on older participants’ health.
Many of these studies have focused on the cognitive con-
sequences of withdrawal [20,29,30]. However, there seems
to be no previous study in elderly outpatients on the effect
of withdrawal from chronic use of temazepam, zopiclone
and zolpidem on handgrip strength and balance. Further-
more, studies exploring balance changes after other ben-
zodiazepines withdrawal are rare and have limitations or
methodological differences compared to our study [17,18].
A controlled trial by Habraken and her colleagues con-
cluded that lorazepam withdrawal improved nursing
home residents’ level of daily functioning [17]. Daily
functioning was assessed using observational data and
no balance test or muscle strength test was performed.
Their sample was limited to nursing home inpatients,
which is different from our setting with relatively well-
conditioned community-dwelling patients.
A recent study by Tsunoda et al. focused on the effects
of benzodiazepine derivative hypnotics’ discontinuation
on postural sway [18]. The 26 participants in the study
were living in nursing homes and had psychiatric diag-
noses – mainly schizophrenia and dementia. Balance
was assessed using the Clinical Stabilometric Platform
(ANIMA® GS-7, Tokyo). After discontinuation of hypnotic
use, the range and total trunk motion length were signifi-
cantly shortened, i.e., balance was improved. However, the
characteristics of that study’s participants differed from
those in our study, as their participants had psychiatric
diagnoses and were significantly older (mean age ± SD was
79.1 ± 8.9 years) than our participants (66.7 ± 6.9 years).
The older and cognitively diminished (Mini Mental
State Examination mean 21.6, SD ±4.8) participants in
Tsunoda’s study were more vulnerable and seem to have
benefited even more from benzodiazepine withdrawal
than our participants did.
Our study has strengths and limitations. First, the
number of participants (altogether 89) is larger than in
other studies that have examined the effect of with-
drawal from chronic use of benzodiazepines on physical
performance [17,18]. However, our study power did not
allow analyzing the effects of temazepam, zopiclone
or zolpidem separately. Second, we confirmed the use
of benzodiazepines at baseline and at the end of the
one-month withdrawal period by measuring plasma
concentrations of individual benzodiazepines. During
the follow-up period, up to six months, information
concerning benzodiazepine use was collected by inter-
views and by checking each patient’s medical records
and prescription history. These methods are reliable,
but using different data collection methods may raise
questions about comparability between the results
from blood samples vs those from interviews or prescrip-
tion records. Third, all of our participants were long-termusers of benzodiazepine hypnotics who voluntarily parti-
cipated in and were well motivated to complete the
benzodiazepine withdrawal study. However, the absence
of an initially benzodiazepine naïve, “pure” control group
leaves open the issue of how a benzodiazepine-free popu-
lation would have performed in the various tests. Finally,
non-withdrawers also markedly reduced their benzodi-
azepine use during the study [19]. This reduction in
benzodiazepine use most likely explains their enhanced
handgrip strength and balance results. The difference be-
tween the results of the withdrawers and non-withdrawers
(more correctly “partial withdrawers”) could have been
clearer if the non-withdrawers had not reduced their
benzodiazepine doses. On the other hand, it is encour-
aging that reduction of benzodiazepine use, and not only
their complete withdrawal, can result in improved muscle
strength and balance in chronic users.
A significant percentage of elderly patients regularly
use benzodiazepines or related drugs [3,31,32], and the
adverse effects of chronic benzodiazepine use on atten-
tional and psychomotor cognitive functioning can persist
for several months after the withdrawal [20]. The present
study demonstrates that beneficial effects of benzodiazep-
ine withdrawal on muscle strength and balance can be
seen within one month after initiating withdrawal. This is
clinically important as impaired muscle strength and bal-
ance are risk factors for falls.
The present study and previous studies from the same
participants show that the laborious withdrawal process
produces good withdrawal outcomes, but some partici-
pants still remain or return regular users of benzodiaze-
pines. Thus, it seems better to avoid prescribing them at
all; that is “prevention is better that cure”. Regardless, our
results encourage discontinuing prolonged use of benzodi-
azepine hypnotics.
Conclusions
An improvement in handgrip strength and balance was
observed in older outpatients after temazepam, zopiclone
and zolpidem withdrawal. These positive effects encour-
age discontinuing long-term use of benzodiazepine-type
hypnotics, particularly in older women who are at a high
risk of sustaining fall and fractures.
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